Gabriel Abreu

A Randomized, <scp>Placebo‐Controlled</scp> Phase <scp>III</scp> Extension Trial of the <scp>Long‐Term</scp> Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Kenneth Kalunian, Richard Furie, Eric F. Morand et al. · Arthritis & Rheumatology · 2022 · 129 citations · Full text

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Edward M Vital, Joan T. Merrill, Eric F. Morand et al. · Annals of the Rheumatic Diseases · 2022 · 125 citations · Full text

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

Raj Tummala, Gabriel Abreu, Lilia Pineda et al. · Lupus Science & Medicine · 2021 · 88 citations · Full text

Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus

Richard Furie, Eric F. Morand, Anca Askanase et al. · Lupus · 2021 · 74 citations

Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study

Winn Chatham, Richard Furie, Amit Saxena et al. · Arthritis & Rheumatology · 2020 · 71 citations · Full text